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Abstract 
Background and Purpose: We assessed safety, feasibility and potential effects of vagus 
nerve stimulation (VNS) paired with rehabilitation for improving arm function after chronic 
stroke. 
Methods: We performed a randomized, multisite, double-blinded, sham-controlled pilot 
study. All participants were implanted with a VNS device and received 6-weeks in-clinic 
rehabilitation followed by a home exercise program. Randomization was to Active VNS 
(n=8) or Control VNS (n=9) paired with rehabilitation. Outcomes were assessed at day 1, 30 
and 90-post completion of in-clinic therapy.  
Results: All participants completed the course of therapy. There were 3 serious adverse 
events related to surgery. Average FMA-UE scores increased 7.6 with Active VNS and 5.3 
points with Control at day-1 post in-clinic therapy (difference=2.3 points, CI: -1.8 to 6.4, 
p=0.20). At day-90, mean scores increased 9.5 points from baseline with Active VNS and the 
Control scores improved by 3.8 (difference=5.7 points; CI: -1.4 to 11.5, p=0.055). The 
clinically meaningful response rate of FMA-UE at day-90 was 88% with Active VNS and 
33% with Control VNS (p<0.05).  
Conclusions: VNS paired with rehabilitation was acceptably safe and feasible in participants 
with upper limb motor deficit after chronic ischemic stroke. A pivotal study of this therapy is 
justified. 
 
Clinical Trial Registration: ClinicalTrials.gov NCT02243020  
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Introduction 
Impaired use of the upper limb is one of the most common symptoms following stroke and 
improving upper limb function is a priority for many patients (1). Clinical trials of increased 
dose of upper extremity task-specific training have been disappointing (2). This suggests new 
interventions are needed to maximize post stroke motor recovery (3). 
Vagus nerve stimulation (VNS) paired with movement has been shown to drive task-specific 
plasticity in the motor cortex in rodent models and improve forelimb function after 
experimental stroke (4). In our first-in-human, randomized, controlled, open clinical trial, 
VNS paired with upper limb rehabilitation was safe and feasible in people with upper limb 
deficit at least 6 months after ischemic stroke (5).  
The purpose of this pilot study was to further assess safety, feasibility and efficacy of VNS 
paired with upper limb rehabilitation in chronic ischemic stroke, with blinded, sham VNS 
control. 
 
Methods  
This manuscript adheres to the AHA Journals' implementation of the Transparency and 
Openness Promotion (TOP) Guidelines. Requests for data will be considered by the 
corresponding author after FDA post market approval. 
This was a randomized, sham stimulation controlled and fully blinded study of VNS paired 
with rehabilitation in people with arm weakness after ischemic stroke.  Participants in both 
groups were implanted with the VNS device. Participants, therapists, and outcome assessors 
were blinded to group allocation.  
The study was approved by an institutional review board at each institution and subject to 
appropriate regulatory approvals (FDA Investigational Device Exemption (IDE, #130287) 
and UK MHRA No #CI/2015/0011). It was registered on clinicaltrials.gov (NCT02243020).  
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Written informed consent was obtained in compliance with the requirements set forth in U.S. 
FDA, Code of Federal Regulations Title 21. The study was conducted according to the 
Declaration of Helsinki. 
Participants 
Enrollment at the four sites is shown in Supplemental Table I. People with a history of 
unilateral supratentorial ischemic stroke that occurred between 4 months to 5 years prior to 
randomization, aged ≥30 years and ≤80 years, and with an FMA-UE between 20-50 were 
eligible for inclusion (Supplemental Table II).  
Protocol Summary 
A pre-surgery assessment was performed. After VNS implantation and approximately one 
week of recovery, participants were randomized to either Active VNS (0.8mA) or Control 
VNS (0.0mA) and baseline assessments were repeated. In-clinic rehabilitation therapy began 
on the next day and was delivered approximately 3 times a week for 6 weeks (18 visits, 
Supplemental Figure I). Outcomes assessments were performed on day-1, day-7, day-30 and 
day-90 following completion of in-clinic therapy. 
Following 6 weeks of in-clinic therapy, all participants began daily, therapist-prescribed 
home exercises. For the first 30 days of at-home therapy, all participants received 0 mA 
VNS. Thereafter, participants received VNS according to their randomized allocation. After 
the day-90 assessment, the Control VNS group crossed over to receive 6-weeks of in-clinic 
rehabilitation paired with Active VNS (0.8mA) followed by outcome assessments at day 1, 7, 
30, and 90 thereafter.  
Further details on methodology are given in the supplementary appendix.  
Main Study Outcome Measures 
The main safety outcome measure was the number of serious adverse events related to the 
device or therapy. The main feasibility measure was number of participants that completed 
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the minimum number of visits during the randomized portion of the study (at least 12 therapy 
visits).  
Efficacy outcomes included the FMA-UE (6), Wolf Motor Function Test (WMFT Time and 
Functional), Box and Block, Nine Hole Peg Test (NHPT), Stroke Impact Scale (SIS) and 
Motor Activity Log (MAL). Since this was a pilot study, no primary or secondary efficacy 
measures were designated.  
Sample Size and Statistical Analysis 
No formal sample size calculation was performed for this pilot study. Efficacy analyses were 
performed on the intention-to-treat (ITT) population and included all randomized 
participants. Missing data were not imputed. The change in outcome measures at each time 
point was compared between groups using two-tailed, unpaired t-tests. Fishers exact test was 
used to calculate the significance for response rates. For all comparisons, alpha was set at 
0.05. 
 
Results  
Twenty-two people consented to participate in the study. Of these, 17 participants were 
implanted and randomized [8 to Active VNS and 9 to Control] (Supplemental Figure II). All 
participants completed the randomized portion of the study.  Baseline characteristics of 
participants are shown in Supplemental Table III. Details on protocol adherence, feasibility 
and blinding are provided in the supplement.  
Safety 
There were three serious adverse events related to implantation surgery including one 
implantation wound infection requiring treatment with intravenous antibiotics but resolved, 
one case of shortness of breath and dysphagia, likely due to intubation, which recovered, and 
one case of hoarseness due to vocal cord palsy.  There were no serious adverse events 
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reported as associated with stimulation.  Full details of adverse events are shown in the 
supplemental appendix.  
Efficacy  
Between group differences in FMA-UE are shown in Figure 1, and Table 1. At day-90, the 
response rate [defined as FMA-UE change ≥ 6 points (7)], was 88% in the Active group and 
33% in Control (p=0.03) (Figure 2).  Between group differences in WMFT are shown in 
Figure 1 and Table 1.  
Following crossover to Active VNS in controls, FMA-UE scores increased to 9.8 points 
above baseline at day-1 after in clinic therapy (p<0.001) and by 6.6 points at day-90 (p=0.01) 
(Figure 1). Response rates were 88% and 57% at these time points respectively (Figure 2). 
WMFT data are shown in Figure 1. Full details on all outcome measures are shown in 
Supplemental Tables V and VI.  
 
Discussion 
The primary objective of this pilot study was to assess the safety and feasibility of using 
paired VNS to improve arm function after chronic ischemic stroke. We found this technique 
to be feasible, including use of home-based VNS, and demonstrated safety in-line with that 
expected for VNS devices. The study was not powered to assess efficacy, although there 
were significant differences between groups in some measures at day-90.   
There are several important differences between this and our previous clinical study (5). This 
study was fully blinded, all participants were implanted with a VNS device, Control 
participants crossed-over to receive the Active VNS therapy, and participants continued 
rehabilitation exercises at home for several months.  
There were no significant differences between groups immediately after in-clinic therapy 
completion, but there was a significant difference by 90-days due to maintained benefit by 
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the VNS group with corresponding decline in the Control group, and a higher percentage of 
responders who achieved a clinically meaningful change for the FMA-UE (change ≥ 6 
points) with Active VNS treatment (7). While we cannot definitively conclude these 
differences are due to paired Active VNS treatment, our findings are consistent with the 
effect of a neuroplastic treatment where time may be needed for benefit to accrue. It is of 
note that Control participants experienced a benefit similar to the initial VNS participants 
when they crossed over to active VNS treatment.  
This pilot study showed that rehabilitation paired with VNS is an acceptably safe and feasible 
intervention for the treatment of upper limb weakness after ischemic stroke. The study 
demonstrated sufficient safety, feasibility and potential efficacy to support a larger pivotal 
trial.  
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Figure Legends 
 
Figure 1. Fugl Meyer Assessment - Upper Extremity (FMA-UE) (mean ± SEM) and 
Wolf Motor Function Test (WMFT) scores (mean ± SEM). A. Change in FMA-UE score 
during blinded follow-up for Active VNS and Controls from baseline and three post-
treatment assessments. B. Change in FMA-UE score following cross-over to active VNS. C. 
Change in WMFT Functional score during blinded follow-up for Active VNS and Controls 
(*= p=0.029 at post-90 and p<0.001 at post-30). D. Change in WMFT score following cross-
over to Active VNS. Shaded area indicates the 6-weeks of in-clinic therapy. Rebase = 
baseline in controls prior to starting Active VNS. Day-1 to Day-30 (after in-clinic therapy) 
consisted of at-home therapy with no VNS for both groups. From Day-30 to Day-90, Active 
VNS group received VNS (0.8 mA) and controls received Control VNS (0 mA) with at-home 
therapy. 
 
Figure 2. Average Fugl Meyer Assessment - Upper Extremity (FMA-UE) Response 
Rate. A. Responder rate (defined as FMA-UE change ≥6 from baseline) for the first 90 days 
in paired VNS (black) and Controls (gray) (*p<0.05, Fishers Exact Test). B. Responder rates 
after control group crossed over to receive active VNS therapy. Rebase = baseline in controls 
prior to starting active VNS therapy. 
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Table 1. Change in Outcome Measures [ITT analysis, n=17 (Active VNS=8; Control=9)] 
 
Measure Day-1 Difference Post In-Clinic 
Therapy* 
Day-90 Difference Post In-Clinic 
Therapy* 
  (95% CI) P Value  (95% CI) P Value 
FMA-UE  2.29 
(-1.9, 6.47) 
0.2604 5.72 (-.15, 11.6) 0.055 
WMFT Functional 0.12 (-.10, 0.33) 0.2625 0.33 (0.04, 0.61) 0.029 
WMFT Time (s)  -3.02 (-11, 5.24) 0.4215 -4.04 (-14, 5.64) 0.362 
SIS (Hand) 5.66 (-11, 22.7) 0.4889 2.71 (-14, 19.9) 0.741 
Box and Block -2.93 (-6.3, 0.44) 0.0835 -0.23 (-4.1, 3.66) 0.903 
Nine Hole Peg -2.25 (-58, 53.5) 0.9245 -9.18 (-48, 29.2) 0.580 
Motor Activity Log NA NA 17.93 (-.37, 36.2) 0.054 
 
FMA-UE = Fugl-Meyer Assessment - Upper Extremity; ITT = intention to treat; NA = not 
applicable; SIS = Stroke Impact Scale; VNS = vagus nerve stimulation; WMFT = Wolf Motor 
Function Test. * difference between groups: Active VNS – Control VNS. 
 
 
